Head to Head Contrast: Argos Therapeutics (OTCMKTS:ARGSQ) and Can-Fite BioPharma (NYSE:CANF)

Argos Therapeutics (OTCMKTS:ARGSQ) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Argos Therapeutics has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Argos Therapeutics and Can-Fite BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Argos Therapeutics	0	0	0	0	N/A
Can-Fite BioPharma	0	0	1	0	3.00

Can-Fite BioPharma has a consensus price target of $15.00, suggesting a potential upside of 365.84%. Given Can-Fite BioPharma’s higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Argos Therapeutics.

Valuation & Earnings

This table compares Argos Therapeutics and Can-Fite BioPharma’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Argos Therapeutics	$1.90 million	0.30	-$40.57 million	N/A	N/A
Can-Fite BioPharma	$740,000.00	15.12	-$7.63 million	($1.79)	-1.77

Can-Fite BioPharma has lower revenue, but higher earnings than Argos Therapeutics.

Insider and Institutional Ownership

21.0% of Can-Fite BioPharma shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Argos Therapeutics and Can-Fite BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Argos Therapeutics	N/A	N/A	N/A
Can-Fite BioPharma	-1,027.46%	-113.75%	-69.91%

Summary

Argos Therapeutics beats Can-Fite BioPharma on 6 of the 11 factors compared between the two stocks.

About Argos Therapeutics

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.